Drug intelligence / Profile preview

AYK103

Development stage: Unknown
Lead developer: MAXVAX Biotechnology
Modality: Vaccines & Immunotherapeutics
Administration: Intratumoral

Overview

AYK103 is an in-situ therapeutic cancer vaccine (tumor vaccine) developed by Chengdu Maxvax Biotechnology and Shanghai AEON Biotechnology. It is designed for the treatment of neoplasms, specifically hepatocellular carcinoma (liver cancer). The vaccine formulation incorporates a novel composite adjuvant system intended to enhance the immune response against tumor cells. As an in-situ vaccine, it is typically administered directly into the tumor site to induce a localized and potentially systemic anti-tumor immune response. AYK103 is currently in Phase 1 clinical development.

Beyond the preview

Go deeper on AYK103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AYK103.

Explore the full profile